Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 247-956-7 | CAS number: 26748-47-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2003-01-14 to 2003-07-24
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 003
- Report date:
- 2003
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Version / remarks:
- adopted 21st July 1997
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
Test material
- Reference substance name:
- 1-methyl-1-phenylethyl peroxyneodecanoate
- EC Number:
- 247-956-7
- EC Name:
- 1-methyl-1-phenylethyl peroxyneodecanoate
- Cas Number:
- 26748-47-0
- Molecular formula:
- C19H30O3
- IUPAC Name:
- 1-methyl-1-phenylethyl 2-ethyl-2,5-dimethylhexaneperoxoate
Constituent 1
- Specific details on test material used for the study:
- - Supplier: ATOFINA
- Chemical Name: Alpha-CUMYL PEROXYNEODECANOATE
- Batch number: 0210840414
- Description: colourless liquid
- Container: one plastic flask
- Storage conditions: at -20 °C and protected from light
- Purity: 75% in isododecane
The test item was dissolved in the vehicle at a concentration of 612.9 mg/mL for the first experiment and 306.45 mg/mL for the second experiment.
The preparations were made immediately before use.
Method
Species / strain
- Species / strain / cell type:
- lymphocytes: human lymphocytes
- Details on mammalian cell type (if applicable):
- CELLS USED
- Cells used: Human lymphocytes
- Modal number of chromosomes: 46
- Cell cycle time: 12 - 14
- Human lymphocytes were prepared from whole blood samples obtained from two healthy donors and collected into heparinised sterile tubes.
MEDIA USED
RPMI 1640 medium containing 20% fetal calf serum, L-glutamine (2 mM), penicillin (100 U/mL), streptomycin (100 μg/mL) and phytohaemagglutinin - Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- Rat liver post-mitochondrial fraction (S9)
- Test concentrations with justification for top dose:
- The highest dose-level for treatment in the first experiment was selected on the basis of pH, osmolality and solubility. For selection of the dose-levels for the second experiment, toxicity indicated by the reduction of mitotic index (MI) in the first experiment, if any, was also taken into account.
- Experiment I (with and without S9): 0.16, 0.31, 0.63, 1.25, 2.5, 5, and 10 mM
- Experiment II (with S9): 0.16, 0.31, 0.63, 1.25, 2.5 and 5 mM
- Experiment II (without S9): 0.04, 0.08, 0.16, 0.31, 0.63 and 1.25 mM - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: Ethanol, batch no. V8M084248 M (Carlo Erba, 27106 Val de Reuil, France)
Controlsopen allclose all
- Untreated negative controls:
- yes
- Remarks:
- distilled water
- Negative solvent / vehicle controls:
- no
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- mitomycin C
- Remarks:
- without S9: 3 µg / mL ( 3h) or 0.2 µg / mL (continuous experiment)
- Untreated negative controls:
- yes
- Remarks:
- distilled water
- Negative solvent / vehicle controls:
- no
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- with S9: 12.5, 25 or 50 µg / mL
- Details on test system and experimental conditions:
- Treatment
In two independent experiments, using duplicate cultures, the cells were tested, with and without S9 mix, with:
- at least five dose-levels of the test item,
- the vehicle control,
- the appropriate positive control.
To prepare each culture, 0.5 mL of heparinised whole blood was added to 5 mL of RPMI 1640 medium containing 20% fetal calf serum, L-glutamine (2 mM), penicillin (100 U/mL), streptomycin (100 μg/mL) and phytohaemagglutinin (PHA: a mitogen to stimulate the lymphocytes to divide). The cultures were then placed at 37°C for 48 hours.
In the first experiment, lymphocyte cultures were then exposed to the test or control items, both in the absence and presence of S9 mix, for 3 hours then rinsed. One and a half hour before harvest, each culture was treated with a colcemid solution (10 μg/mL) to block cells at the metaphase-stage of mitosis. Harvest time was 20 hours from the beginning of treatment, corresponding to approximately 1.5 normal cell cycles.
The second experiment was performed as follows:
• without S9 mix, cells were exposed continuously to the test or control items, until harvest,
• with S9 mix, cells were exposed to the test or control items for 3 hours and then rinsed.
One and a half hour before harvest, each culture was treated with a colcemid solution (10 μg/mL) to block cells at the metaphase-stage of mitosis. Harvest times were 20 hours and 44 hours from the beginning of treatment, corresponding to approximately 1.5 normal cell cycles and 24 hours later.
Preparation of microscope slides
After hypotonic treatment (KCl 0.075 M), the cells were fixed in a methanol/acetic acid mixture (3/1; v/v), spread on glass slides and stained with Giemsa. All the slides were coded, so that the scorer is unaware of the treatment group of the slide under evaluation ("blind" scoring).
Determination of cytotoxicity
The cytotoxicity of the test item was evaluated using the mitotic index (number of cells in mitosis/1000 cells examined), which indicates whether a item induces mitotic inhibition. Mitotic index was determined without blind scoring. Analysis of 200 metaphases/dose-level (with 44 to 46 chromosomes) was made, with 100 metaphases/culture whenever possible. Only 50 metaphases/culture were analysed when at least 10% cells with structural chromosome aberrations were observed. All metaphase analyses were performed blind. The following structural aberrations were recorded for each metaphase (c, d): gaps, chromatid and chromosome breaks and exchanges, and others (multiple aberrations and pulverizations). In addition, the following numerical aberrations were recorded when encountered: polyploidy and endoreduplication. The metaphase analysis of the slides was performed at Microptic, cytogenetic services (2 Langland Close Mumbles, Swansea SA3 4LY, UK), in compliance with GLP, and the Principal Investigator was Natalie Danford. - Evaluation criteria:
- A reproducible and statistically significant increase in the frequency of cells with structural chromosome aberrations for at least one of the dose-levels and one of the two harvest times was considered as a positive result. Reference to historical data or other considerations of biological relevance, was also taken into account in the evaluation of the findings.
- Statistics:
- For each test and for each harvest time, the frequency of cells with structural chromosome aberrations (excluding gaps) in treated cultures was compared to that of the vehicle control cultures. If necessary, the comparison was performed using the χ2 test, in which p= 0.05 was used as the lowest level of significance.
Results and discussion
Test results
- Species / strain:
- lymphocytes: human
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH and osmolality: pH was approximately 7.7 (7.4 for the vehicle control) and the osmolality equal to 313 mOsm/kg H2O (377 for the vehicle control).
- Other confounding effects: No emulsion was observed in the culture medium at the end of the treatment period.
Experiments without S9 mix:
Cytotoxicity:
Following the 3-hour treatment, a moderate to marked decrease in mitotic index (56-81% decrease) was noted at dose-levels ≥ 1.25 mM. Following the 20-hour treatment, a moderate decrease in mitotic index (41% decrease) was noted at 1.25 mM. Following the 44-hour treatment, a slight to marked decrease in mitotic index (31-70% decrease) was noted at dose-levels ≥ 0.63 mM.
Metaphase analysis:
The dose-levels selected for metaphase analysis were as follows:
- 0.31, 0.63 and 1.25 mM for the 3-hour and the 20-hour treatments, the latter inducing 56 and 41% decreases in mitotic index, respectively,
- 1.25 mM, for the 44-hour treatment, this dose-level inducing 70% decrease in mitotic index.
No significant increase in the frequency of cells with structural chromosomal aberrations was noted after 3, 20 as well as 44-hour treatments.
Experiments with S9 mix:
Cytotoxicity:
A slight to marked decrease in mitotic index (29-78% decrease) was noted at dose-levels ≥ 0.63 mM at the 20-hour harvest time.
At the 44-hour harvest time, a moderate to strong decrease in mitotic index was noted at dose-levels ≥ 1.25 mM (59-89% decrease).
Metaphase analysis:
The dose-levels selected for metaphase analysis were as follows:
- 1.25, 2.5 and 5 mM, for the 20-hour harvest time in the first experiment, the latter inducing 59% decrease in mitotic index,
- 0.31, 0.63 and 1.25 mM, for the 20-hour harvest time in the second experiment, the latter inducing 68% decrease in mitotic index,
- 1.25 mM, for the 44-hour harvest time, this dose-level inducing 59% decrease in mitotic index.
No significant increase in the frequency of cells with structural chromosomal aberrations was noted in both experiments and at both harvest times. The frequencies of cells with structural chromosome aberrations of the vehicle and positive controls were as specified in acceptance criteria. The study was therefore considered valid. The frequencies of cells with structural chromosome aberrations of the vehicle and positive controls were as specified in acceptance criteria. The study was therefore considered valid.
Any other information on results incl. tables
Table 1: Experiment 1 without S9 mix: chromosome aberration (3 -hour treatment, 20 -hour harvest)
Doses mM | Slide Nb. | Nb. Of cells scored | NA | Structural chromosome aberrations (type and number) |
Cells with structural chromosome aberrations | |||||||||||
G | Chromatid | Chromosome | MA | PU | Total +G |
Total -G |
Nb. +G |
% | Nb. -G |
% | ||||||
D | Exch | D | Exch | |||||||||||||
0 | 14M | 100 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 5 | 3 | 1 | 2.0 | 1 | 1.5 |
23F | 100 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 3 | 2 | |||||
0.31 | 22M | 100 | 1 | 2 | 1 | 0 | 2 | 2 | 0 | 0 | 9 | 7 | 6 | 4.0 | 4 | 3.0 |
6F | 100 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 2 | |||||
0.63 | 5M | 100 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 2 | 2 | 3.0 | 0 | 1.0 |
15F | 100 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | |||||
1.25 | 39M | 100 | 2 | 3 | 1 | 0 | 1 | 1 | 0 | 0 | 10 | 5 | 6 | 5.0 | 3 | 2.5 |
12F | 100 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | |||||
MMC | 9M | 50 | 0 | 4 | 18 | 11 | 3 | 0 | 0 | 0 | 89 | 78 | 21 | 52.0 | 19 | 48.0 *** |
3µg/mL | 18F | 50 | 0 | 7 | 28 | 14 | 4 | 0 | 0 | 0 | 31 | 29 |
Table 2: Second experiment without S9 mix: chromosome aberration (20
-hour treatment, 20 -hour harvest)
Doses mM | Slide Nb. | Nb. of cells scored | NA | Structural chromosome aberrations (type and number) |
Cells with structural chromosome aberrations | |||||||||||
G | Chromatid | Chromosome | MA | PU | Total +G |
Total -G |
Nb. +G |
% | Nb. -G |
% | ||||||
D | Exch | D | Exch | |||||||||||||
0 | 48M | 100 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 5 | 3 | 4 | 2.5 | 1 | 1.5 |
57F | 100 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | |||||
0.31 | 51M | 100 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1.5 | 4 | 0.5 |
75F | 100 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | |||||
0.63 | 64M | 100 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 6 | 1 | 2 | 3.0 | 0 | 0.5 |
44F | 100 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | |||||
1.25 | 60M | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 0 | 1.5 | 3 | 1.0 |
71F | 100 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | |||||
MMC | 54M | 50 | 0 | 3 | 5 | 4 | 1 | 0 | 0 | 0 | 30 | 23 | 10 | 24.0 | 19 | 21.0 *** |
3 µg/mL | 49F | 50 | 0 | 4 | 6 | 5 | 2 | 0 | 0 | 0 | 14 | 29 |
Table 3: Experiment 2 without S9 mix: chromosome aberration (44 -hour
treatment, 44 -hour harvest)
Doses mM | Slide Nb. | Nb. of cells scored | NA | Structural chromosome aberrations (type and number) |
Cells with structural chromosome aberrations | |||||||||||
G | Chromatid | Chromosome | MA | PU | Total +G |
Total -G |
Nb. +G |
% | Nb. -G |
% | ||||||
D | Exch | D | Exch | |||||||||||||
0 | 84M | 100 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 4 | 2 | 4 | 2.0 | 2 | 1.0 |
97F | 100 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Jan 25 | 81M | 52 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 15 | 11 | 3 | 5.5 | 2 | 3.5 |
87F | 148 | 3 | 3 | 2 | 0 | 7 | 0 | 0 | 0 | 8 | 5 |
Table 4: Experiment 1 with S9 mix: chromosome aberration (3 -hour treatment, 20 -hour harvest)
Doses mM | Slide Nb. | Nb. of cells scored | NA | Structural chromosome aberrations (type and number) |
Cells with structural chromosome aberrations | |||||||||||
G | Chromatid | Chromosome | MA | PU | Total +G |
Total -G |
Nb. +G |
% | Nb. -G |
% | ||||||
D | Exch | D | Exch | |||||||||||||
0 | 32M | 100 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 5 | 3 | 2 | 2.5 | 1 | 1.5 |
8F | 100 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 2 | |||||
1.25 | 2M | 100 | 1 | 4 | 0 | 0 | 1 | 0 | 0 | 0 | 9 | 2 | 5 | 4.5 | 1 | 1.0 |
33F | 100 | 1 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 4 | 1 | |||||
2.5 | 38; | 100 | 2 | 3 | 1 | 0 | 1 | 1 | 0 | 0 | 13 | 9 | 6 | 5.5 | 3 | 3.5 |
26F | 100 | 1 | 1 | 3 | 0 | 3 | 0 | 0 | 0 | 5 | 4 | |||||
5 | 16M | 100 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 1 | 7 | 5.0 | 0 | 0.5 |
4F | 100 | 3 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 1 | |||||
CPA | 27M | 50 | 0 | 6 | 26 | 5 | 1 | 0 | 0 | 0 | 91 | 78 | 22 | 52.0 | 21 | 48.0 *** |
50 µg/mL | 17F | 50 | 0 | 7 | 35 | 6 | 4 | 0 | 1 | 0 | 30 | 27 |
Table 5: Experiment 2 with S9 mix: chromosome aberration (4 -hour treatment 20 -hour harvest)
Doses mM | Slide Nb. | Nb. Of cells scored | NA | Structural chromosome aberrations (type and number) |
Cells with structural chromosome aberrations | ||||||||||
Chromatid | Chromosome | MA | PU | Total +G |
Total -G |
Nb. +G |
% | Nb. -G |
% | ||||||
D | Exch | D | Exch | ||||||||||||
0 | 43M | 100 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 5 | 4 | 1 | 2.5 | 1 | 2.0 |
53F | 100 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 4 | 3 | |||||
0.31 | 52M | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 1.5 | 0 | 0.5 |
69F | 100 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | |||||
0.63 | 66M | 100 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 5 | 4 | 1 | 2.0 | 1 | 1.5 |
47F | 100 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 3 | 2 | |||||
Jan 25 | 56M | 100 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 6 | 4 | 3 | 3.0 | 1 | 2.0 |
72F | 100 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 3 | 3 | |||||
CPA | 73M | 50 | 0 | 10 | 3 | 3 | 0 | 0 | 0 | 38 | 31 | 16 | 28.0 | 13 | 23.0 *** |
12.5 µg/mL | 45F | 50 | 0 | 12 | 2 | 1 | 0 | 0 | 0 | 12 | 10 |
Table 6: Experiment 2 with S9 mix: chomosome aberration (3 -hour treatment 44 -hour harvest)
Doses mM | Slide Nb. | Nb. Of cells scored | NA | Structural chromosome aberrations (type and number) |
Cells with structural chromosome aberrations | ||||||||||
Chromatid | Chromosome | MA | PU | Total +G |
Total -G |
Nb. +G |
% | Nb. -G |
% | ||||||
D | Exch | D | Exch | ||||||||||||
0 | 77M | 100 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 1 | 2 | 1.5 | 1 | 0.5 |
91F | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | |||||
1.25 | 83M | 100 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 5 | 2 | 3 | 2.5 | 1 | 1.0 |
94F | 100 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 1 |
NA: numerical aberrations, G: gap, D: deletion, Exch: exchange, MA: multiple aberrations, PU: pulverization.
M: male
F: female
0: vehicle control (DMSO)
MMC: mitomycin C
Statistical analysis: Chi-Quadrat test ***: p < 0.001 (performed only for cells with structural aberrations excluding gaps)
Nb.: number
(1): expressed as active
Applicant's summary and conclusion
- Conclusions:
- In this study, the test substance did not induce chromosome aberrations in the performed experiments with or without metabolic activation. Therefore, the test item is not considered to be clastogenic in this test system.
- Executive summary:
In an in-vitro mammalian chromosome aberration test conducted in accordance with OECD 473, the potential of the test item (75% in isododecane) to induce chromosome aberrations in cultured human lymphocytes was evaluated in the presence and absence of a liver metabolizing system (S9). In the first experiment, lymphocytes were exposed to 0.16, 0.31, 0.63, 1.25, 2.5, 5, and 10 mM with and without S9 mix for 3 hours, then rinsed. Cells were harvested 20 hours after beginning of treatment. For the second experiment, the cells were treated with 0.16, 0.31, 0.63, 1.25, 2.5 and 5 mM with S9 mix for 3 hours, then rinsed and with 0.04, 0.08, 0.16, 0.31, 0.63 and 1.25 mM without S9 mix until harvest. Cells were harvested 20 and 44 hours after the beginning of treatment. For all tested treatment groups, no dose-response relationship could be observed. The positive controls did induce the appropriate response. There was no significant increase in the frequency of cells with structural chromosomal aberrations in both experiments and at both harvest times. Based on these results, the test item did not induce chromosome aberrations in cultured human lymphocytes.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.